17:00 Mon 01 Jul 2019
Scancell Hlds - H1 2019 Business Update
("Scancell" or the "Company")
H1 2019 Business Update
Scancell, the developer of novel immunotherapies for the treatment of cancer, today announces a business update following the progress made in H1 2019.
SCIB1 Phase 2 trial
As reported in April, the Company has received the necessary regulatory and ethical approvals to initiate the
Modi-1 manufacturing and preclinical programme
In May, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial, with initiation of Good Manufacturing Practice (GMP) synthesis of the Modi-1 peptide conjugates at the
Cancer Research
Scancell and
Strengthened team and
In January, Scancell strengthened its team by appointing Dr
Strengthened IP portfolio
During this period, the Company was granted a US patent that provides protection for Modi-1, the first clinical candidate from Scancell's Moditope® platform, a patent that provides protection for the Moditope® platform in
Vulpes investment and Board position
In June, Scancell raised gross proceeds of
Dr
"It has been a busy and productive six months for Scancell. We were pleased to welcome Vulpes as a shareholder in June and their investment not only strengthens our cash position, but provides a ringing endorsement of Scancell's future potential. We look forward to working with Martin Diggle, who will provide valuable insight as a Non-Executive Director.
In addition to expanding our team and establishing a
For Further Information:
|
|
|
Dr |
|
+44 (0) 20 3727 1000 |
Dr |
|
|
|
|
|
(Nominated Adviser and Corporate broker) |
|
|
|
|
+44 (0) 20 7886 2500 |
|
|
|
FTI Consulting |
|
+44 (0) 20 3727 1000 |
|
|
|
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
For further details, please see our website: www.scancell.co.uk
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE